Literature DB >> 18452230

Immobilization strategies for single-chain antibody microarrays.

Shannon L Seurynck-Servoss1, Cheryl L Baird, Keith D Miller, Noah B Pefaur, Rachel M Gonzalez, David O Apiyo, Heather E Engelmann, Sudhir Srivastava, Jacob Kagan, Karin D Rodland, Richard C Zangar.   

Abstract

Sandwich ELISA microarrays have great potential for validating disease biomarkers. Each ELISA relies on robust-affinity reagents that retain activity when immobilized on a solid surface or when labeled for detection. Single-chain antibodies (scFv) are affinity reagents that have greater potential for high-throughput production than traditional IgG. Unfortunately, scFv are typically less active than IgG following immobilization on a solid surface and not always suitable for use in sandwich ELISAs. We therefore investigated different immobilization strategies and scFv constructs to determine a more robust strategy for using scFv as ELISA reagents. Two promising strategies emerged from these studies: (i) the precapture of epitope-tagged scFv using an antiepitope antibody and (ii) the direct printing of a thioredoxin (TRX)/scFv fusion protein on glass slides. Both strategies improved the stability of immobilized scFv and increased the sensitivity of the scFv ELISA microarray assays, although the antiepitope precapture method introduced a risk of reagent transfer. Using the direct printing method, we show that scFv against prostate-specific antigen (PSA) are highly specific when tested against 21 different IgG-based assays. In addition, the scFv microarray PSA assay gave comparable quantitative results (R(2) = 0.95) to a commercial 96-well ELISA when tested using human serum samples. In addition, we find that TRX-scFv fusions against epidermal growth factor and toxin X have good LOD. Overall, these results suggest that minor modifications of the scFv construct are sufficient to produce reagents that are suitable for use in multiplex assay systems.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452230     DOI: 10.1002/pmic.200701036

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  6 in total

Review 1.  Photonic crystal enhanced fluorescence for early breast cancer biomarker detection.

Authors:  Brian T Cunningham; Richard C Zangar
Journal:  J Biophotonics       Date:  2012-06-27       Impact factor: 3.207

2.  Use of a single-chain antibody library for ovarian cancer biomarker discovery.

Authors:  Arturo B Ramirez; Christian M Loch; Yuzheng Zhang; Yan Liu; Xiaohong Wang; Elizabeth A Wayner; Jonathon E Sargent; Sahar Sibani; Eugenie Hainsworth; Eliseo A Mendoza; Ralph Eugene; Joshua Labaer; Nicole D Urban; Martin W McIntosh; Paul D Lampe
Journal:  Mol Cell Proteomics       Date:  2010-05-13       Impact factor: 5.911

3.  Flow cytometry-based methods for assessing soluble scFv activities and detecting antigens in solution.

Authors:  Sean A Gray; Kris M Weigel; Keith D Miller; Joseph Ndung'u; Philippe Büscher; Thao Tran; Cheryl Baird; Gerard A Cangelosi
Journal:  Biotechnol Bioeng       Date:  2010-04-01       Impact factor: 4.530

4.  Diet-induced obesity reprograms the inflammatory response of the murine lung to inhaled endotoxin.

Authors:  Susan C Tilton; Katrina M Waters; Norman J Karin; Bobbie-Jo M Webb-Robertson; Richard C Zangar; K Monica Lee; Diana J Bigelow; Joel G Pounds; Richard A Corley
Journal:  Toxicol Appl Pharmacol       Date:  2013-01-07       Impact factor: 4.219

5.  A Combinatory Antibody-Antigen Microarray Assay for High-Content Screening of Single-Chain Fragment Variable Clones from Recombinant Libraries.

Authors:  Nina Persson; Bo Jansson; Nicolai Stuhr-Hansen; András Kovács; Charlotte Welinder; Lena Danielsson; Ola Blixt
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

Review 6.  Current applications of antibody microarrays.

Authors:  Ziqing Chen; Tea Dodig-Crnković; Jochen M Schwenk; Sheng-Ce Tao
Journal:  Clin Proteomics       Date:  2018-02-28       Impact factor: 3.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.